Fieuws, Charlotte http://orcid.org/0000-0002-1567-2075
Van der Meulen, Joni http://orcid.org/0000-0002-1916-2769
Proesmans, Kristiaan http://orcid.org/0000-0002-7787-9397
De Jaeghere, Emiel A.
Loontiens, Siebe http://orcid.org/0000-0002-4602-4580
Van Dorpe, Jo http://orcid.org/0000-0001-8175-2930
Tummers, Philippe
Denys, Hannelore http://orcid.org/0000-0002-8897-9430
Van de Vijver, Koen
Claes, Kathleen B. M. http://orcid.org/0000-0003-0841-7372
Funding for this research was provided by:
Fonds Wetenschappelijk Onderzoek (1S73622N, 1S73622N)
Article History
Received: 5 October 2023
Accepted: 8 March 2024
First Online: 22 March 2024
Competing interests
: H.D. reports consulting fees (advisory role) paid to her institution by Pfizer, Roche, PharmaMar, AstraZeneca, Eli Lilly, Novartis, Amgen, GSK, MSD, Seagen, Gilead and other fees paid to her institution (travel, accommodations, expenses) by Pfizer, Roche, PharmaMar, Teva, AstraZeneca, MSD, GSK, Gilead and an institutional research grant by Gilead.